Search our Database of Scientific Publications and Authors

I’m looking for a

    8123 results match your criteria Metastatic Carcinoma of the Skin

    1 OF 163

    Frequency and locations of systemic metastases in Merkel cell carcinoma by imaging.
    Acta Radiol Open 2017 Mar 24;6(3):2058460117700449. Epub 2017 Mar 24.
    Medical Imaging Center, Helsinki University Hospital, Helsinki, Finland.
    Background: The primary neuroendocrine skin cancer, Merkel cell carcinoma (MCC), has a well-known predilection to metastasize systemically. However, the experience of systemic metastases in MCC is mainly disseminated through case reports due to the rarity of MCC.

    Purpose: To elucidate the frequency and locations of systemic metastasis in MCC by reviewing the imaging of patients with metastatic MCC in a national cohort. Read More

    "Clown nose" as first manifestation of squamous cell carcinoma of the lung.
    J Dermatol Case Rep 2017 Mar 31;11(1):9-11. Epub 2017 Mar 31.
    Department of Dermatology, IDIBELL, Hospital de Bellvitge, University of Barcelona, Barcelona, Spain.
    Background: Skin metastases occur in 0.7% to 9% of all patients with cancer and are usually considered a late event in the evolution of most visceral carcinomas. The development of a nodular metastatic lesion on the nasal tip is known as clown nose sign. Read More

    Ductal eccrine carcinoma of the axilla: a diagnostic pitfall.
    An Bras Dermatol 2017 Mar-Apr;92(2):239-242
    Department of Dermatology, Instituto Português de Oncologia de Lisboa - Lisboa, Portugal.
    Ductal eccrine carcinoma (DEC) is a rare sweat gland carcinoma with ductular differentiation. Clinically, it is characterized by a slowly growing, hardened plaque or nodule predominantly located on the head and neck. Histologically, DEC shares similar features to invasive breast carcinoma, thus causing great diagnostic challenges. Read More

    A nodule on the scalp as the first sign of extranodal disease in medullary thyroid carcinoma.
    Dermatol Online J 2017 May 15;23(5). Epub 2017 May 15.
    Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Spain.
    Medullary carcinoma of the thyroid gland accounts for only 5-10% of thyroid carcinomas. Also, metastases to the skin of malignant tumors are infrequently (2-9% of patients). In the case herein reported in a 64-year old woman, a metastatic nodule on the scalp was the presenting clinical manifestation of a medullary thyroid carcinoma. Read More

    U.S. Food and Drug Administration Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy.
    Oncologist 2017 May 22. Epub 2017 May 22.
    Office of Hematology and Oncology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
    On August 5, 2016, the U.S. Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA injection, Merck Sharp & Dohme Corp. Read More

    A single-center experience of sorafenib monotherapy in patients with advanced intrahepatic cholangiocarcinoma.
    Oncol Lett 2017 May 13;13(5):2957-2964. Epub 2017 Mar 13.
    Department of Hepatic Surgery, Affiliated Provincial Hospital of Anhui Medical University, Hefei, Anhui 230001, P.R. China.
    Patients with advanced intrahepatic cholangiocarcinoma (ICC) have a poor prognosis and the therapeutic options available for treating ICC are limited. Sorafenib, a multikinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet derived growth factor receptor-β, B-Raf proto-oncogene, serine/threonine kinase and C-Raf proto-oncogene, serine/threonine kinase, is a novel reference standard for the treatment of advanced hepatocellular carcinoma. Sorafenib has previously been demonstrated to exhibit significant antitumor activity in various cholangiocarcinoma cell lines and in xenograft ICC models. Read More

    Tumor cell-specific AIM2 regulates growth and invasion of cutaneous squamous cell carcinoma.
    Oncotarget 2017 May 2. Epub 2017 May 2.
    Department of Dermatology, University of Turku and Turku University Hospital, Turku, Finland.
    Cutaneous squamous cell carcinoma (cSCC) is the most common metastatic skin cancer. Inflammation is a typical feature in cSCC progression. Analysis of the expression of inflammasome components in cSCC cell lines and normal human epidermal keratinocytes revealed upregulation of the expression of AIM2 mRNA and protein in cSCC cells. Read More

    An immunohistochemical analysis of lymphocytic infiltrations in canine skin cancers.
    Pol J Vet Sci 2017 Mar;20(1):141-147
    Lymphocytic infiltrations located in the extracellular matrix often accompany canine skin cancer. They can be characterised as an inflammatory infiltration and/or a second tumour - lymphoma. The aim of this study was an immunohistochemical analysis of a lymphocytic infiltration which accompanies spontaneous skin cancer. Read More

    Expression of PD-L1 in keratoacanthoma and different stages of progression in cutaneous squamous cell carcinoma.
    Cancer Immunol Immunother 2017 May 13. Epub 2017 May 13.
    Skin Cancer Center of the Department of Dermatology, St. Josef Hospital, Ruhr-University Bochum, Gudrunstr. 56, 44791, Bochum, Germany.
    Background: Programmed cell death 1 (PD-1) and its ligands (PD-L1) play a major role in the immune responses of a variety of cancers.

    Objectives: To investigate the expression of PD-L1 in different progression forms of cutaneous squamous cell carcinoma (cSCC) and keratoacanthoma (KA).

    Methods: We performed immunohistochemical staining of 21 KA, 26 actinic keratoses (AK), 20 Bowen´s diseases (BD), and 26 high-risk cSCC. Read More

    Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF(V600) mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis.
    Eur J Cancer 2017 May 11;79:176-184. Epub 2017 May 11.
    Cancer Clinical Trials Unit, Royal Adelaide Hospital, Adelaide, Australia; Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, Australia; Discipline of Medicine, University of Adelaide, Adelaide, Australia. Electronic address:
    Background: The orally available BRAF kinase inhibitor vemurafenib is an effective and tolerable treatment option for patients with metastatic melanoma harbouring BRAF(V600) mutations. We assessed the safety of vemurafenib in a large population of patients with few alternative treatment options; we report updated 2-year safety.

    Methods: This was an open-label, multicentre study of vemurafenib (960 mg bid) in patients with previously treated or untreated BRAF mutation-positive metastatic melanoma (cobas(®) 4800 BRAF V600 Mutation Test). Read More

    The cost of major head and neck cancer surgery.
    N Z Med J 2017 May 12;130(1455):111-119. Epub 2017 May 12.
    Wellington Regional Plastic, Maxillofacial and Burns Unit, Hutt Hospital; and Gillies McIndoe Research Institute, Wellington.
    Aim: This study quantified the cost of major head and neck cancer (HNC) surgery.

    Methods: Consecutive patients undergoing major HNC surgery between July 2007 and June 2012 were identified from our head and neck database. Patient demographics, tumour type, site, stage and types of resection and reconstruction, length of stay and surgical complications occurring within six months of initial surgery were retrospectively analysed. Read More

    Estrogen receptor-positive primary squamous cell carcinoma of the breast.
    Radiol Case Rep 2017 Jun 4;12(2):211-214. Epub 2017 Feb 4.
    Department of Diagnostic Radiology, Moffitt Cancer Center, 12902 USF Magnolia Drive, Tampa, FL 33612, USA.
    Pure primary squamous cell carcinoma of the breast (SCCB) represents around 0.1% of breast carcinomas. Diagnosis requires independence from adjacent skin without metastatic disease. Read More

    Breast metastases from extramammary malignancies: multimodality imaging aspects.
    Br J Radiol 2017 May 25:20170197. Epub 2017 May 25.
    1 Department of Imaging, AC Camargo Cancer Center, São Paulo, São Paulo, Brazil.
    Breast metastases from extramammary cancers are rare and usually related to poor prognosis. The extramammary tumours most frequently exhibiting breast metastases are melanoma, lymphomas, ovarian cancer, lung and neuroendocrine tumours, and sarcomas. Owing to the lack of reliable and specific clinical or radiological signs for the diagnosis of breast metastases, a combination of techniques is needed to differentiate these lesions from primary breast carcinoma or even benign breast lesions. Read More

    Unusual asymptomatic presentation of bladder cancer metastatic to the penis.
    Pathol Res Pract 2016 Dec 2. Epub 2016 Dec 2.
    Department of Histology and Molecular Pathology, Careggi Hospital, University of Florence, Largo Brambilla, 3, 50134 Florence, Italy.
    Penile metastasis is an extremely rare event and mainly originate from primary pelvic tumor sites such us urinary bladder, gastro-intestinal tract and prostate and more rarely from respiratory system, bone tumors and melanoma. Here we describe the unusual presentation of two bladder urothelial cancer metastatic to the penis with no relevant clinical symptoms. Namely, a 69 years-old man with a warthy lesions of the foreskin and the glans misunderstood for a condylomata that at histological and immunohistochemical analysis showed a bladder urothelial carcinoma; and a 71 years-old man with reddish skin lesion of the glans, a previous history of bladder and urethral carcinoma and histological pagetoid spread of urothelial cancer to the glans. Read More

    A case of HER2-positive male occult breast carcinoma with skin and lymph node metastases that exhibited complete response to trastuzumab monotherapy.
    Clin Case Rep 2017 May 17;5(5):591-593. Epub 2017 Mar 17.
    Division of Digestive and General SurgeryRyukyu University Graduate School of MedicineOkinawaJapan.
    Metastatic male occult HER2-positive breast cancer can be successfully treated with trastuzumab monotherapy. Read More

    The PP4R1 sub-unit of protein phosphatase PP4 is essential for inhibition of NF-κB by merkel polyomavirus small tumour antigen.
    Oncotarget 2017 Apr;8(15):25418-25432
    School of Molecular and Cellular Biology, Faculty of Biological Sciences, Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds, UK.
    Merkel cell carcinoma (MCC) is a highly aggressive skin cancer with a high metastatic potential. The majority of MCC cases are caused by the Merkel cell polyomavirus (MCPyV), through expression of the virus-encoded tumour antigens. Whilst mechanisms attributing tumour antigen expression to transformation are being uncovered, little is known of the mechanisms by which MCPyV persists in the host. Read More

    Non-melanoma skin cancer: new and future synthetic drug treatments.
    Expert Opin Pharmacother 2017 May 17;18(7):689-699. Epub 2017 Apr 17.
    a Center for Dermatooncology, Department of Dermatology , University Hospital Tübingen , Tübingen , Germany.
    Introduction: Non-melanoma skin cancers (NMSC) mainly comprise two different entities: basal cell carcinoma (BCC) and squamous cell carcinoma (SCC); beneath these two entities, Merkel cell carcinoma, adnexal tumors, dermatofibrosarcoma protuberans, angiosarcoma, and cutaneous lymphoma belong to NMSC. These rare skin tumors are not the topic of this review. BCC and SCC are the most common cancers diagnosed in humans. Read More

    CYFIP1 is directly controlled by NOTCH1 and down-regulated in cutaneous squamous cell carcinoma.
    PLoS One 2017 14;12(4):e0173000. Epub 2017 Apr 14.
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
    Squamous cell carcinoma of the skin (SCC) represents one of the most common cancers in the general population and is associated with a substantial risk of metastasis. Previous work uncovered the functional role of CYFIP1 in epithelial tumors as an invasion inhibitor. It was down-regulated in some cancers and correlated with the metastatic properties of these malignant cells. Read More

    Local treatment of a pharyngocutaneous fistula secondary to osteoradionecrosis.
    Enferm Clin 2017 May - Jun;27(3):193-202. Epub 2017 Apr 11.
    Servicio de Digestivo y Otorrinolaringología, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, España. Electronic address:
    Radionecrosis is a late, and difficult to treat,complication of radiotherapy performed on head and neck tumours, and it is difficult to treat. This process causes significant damage, not only in the skin, but also in muscular, nervous, vascular, and bone structures. This, in turn, leads to airway and digestive tract involvement, as well as a functional loss and a cosmetic defect that usually requires reconstructive surgery. Read More

    MGMT promoter methylation status in Merkel cell carcinoma: in vitro versus invivo.
    J Cancer Res Clin Oncol 2017 Apr 12. Epub 2017 Apr 12.
    Department of Translational Skin Cancer Research (tscr), University Hospital Essen, Universitätstraße 1, 45141, Essen, Germany.
    Purpose: Expression of O6-methylguanine-DNA methyltransferase (MGMT) in Merkel cell carcinoma (MCC) is very variable; thus, we tested whether this may be due to differential methylation of the MGMT gene promoter.

    Methods: Quantitative analysis of MGMT mRNA and protein expression, as well as MGMT promoter methylation status, was performed in a series of tissue samples of MCC tumors, representing both primary and metastatic lesions, as well as in six MCC cell lines.

    Results: These analyses revealed a very heterogeneous MGMT mRNA and protein expression in MCC both in vivo and in vitro. Read More

    Cutaneous basal cell carcinoma with distant metastasis to thorax and bone : A clinicopathological and immunohistochemical study of 15 cases.
    Virchows Arch 2017 Apr 8. Epub 2017 Apr 8.
    Department of Pathology, MD Anderson Cancer Center, Houston, TX, 77030, USA.
    Basal cell carcinoma (BCC) is the most common cutaneous malignancy and is characterized by a high cure rate after local excision. Metastatic BCC (mBCC) is an exceedingly rare event, associated with poor prognosis. We report clinicopathological and immunohistochemical features of 15 mBCC metastatic to the thorax and bone. Read More

    [Why is it important to differentiate trichoblastic carcinomas (CT) from basal cell carcinomas (CBC). About 21 cases].
    Ann Chir Plast Esthet 2017 Apr 3. Epub 2017 Apr 3.
    Service de chirurgie plastique, reconstructrice et esthétique, hôpitaux universitaire de Strasbourg, 67000 Strasbourg, France.
    Trichoblastic carcinoma is a rare epithelial malignant epithelial tumor, its diagnosis is difficult and the therapeutic management is non-consensual. This retrospective study, carried out between 2009 and 2015, covered 21 cases and analyzed the diagnostic and therapeutic characteristics of trichoblastic carcinomas. Sex ratio is 2. Read More

    Axillary skin metastasis of renal cell carcinoma-Case report.
    Int J Surg Case Rep 2017 18;34:74-76. Epub 2017 Mar 18.
    University of Medicine and Pharmacy "Dr. Carol Davila", Bucharest, Romania; University Emergency Central Military Hospital "Dr. Carol Davila", Bucharest, Romania.
    Introduction: Metastatic diseases are seen in approximately 25% of all cases with renal cell carcinoma and sometimes they can appear in unusual sites.

    Case Presentation: We present a 35-year old patient with a painful left axillary mass which causes the functional impairment of the left arm. The axillary mass appeared 2 years after the nephrectomy performed for a left renal cell carcinoma. Read More

    Reviewing the genetic alterations in high-risk cutaneous squamous cell carcinoma: A search for prognostic markers and therapeutic targets.
    Head Neck 2017 Apr 3. Epub 2017 Apr 3.
    Illawarra Health and Medical Research Institute (IHMRI), Northfields Avenue, Wollongong, New South Wales, 2522, Australia.
    Cutaneous squamous cell carcinoma (SCC) is second only in incidence to basal cell carcinoma (BCC), effecting up to 500 000 people in the United States annually. Metastasis to regional lymph nodes occurs in approximately 5% of cases and imparts significant morbidity. Standard treatment in this group involves a combination of surgery and adjuvant radiation. Read More

    Diagnostic accuracy of confocal microscopy imaging versus punch biopsy for diagnosing and subtyping basal cell carcinoma.
    J Eur Acad Dermatol Venereol 2017 Apr 1. Epub 2017 Apr 1.
    Academic Medical Centre, Department of Dermatology, Amsterdam, The Netherlands.
    Background: In vivo reflectance confocal microscopy (RCM) is a promising non-invasive skin imaging technique that could facilitate early diagnosis of basal cell carcinoma (BCC) instead of routine punch biopsies. However, the clinical value and utility of RCM versus a punch biopsy in diagnosing and subtyping BCC is unknown.

    Objective: To assess diagnostic accuracy of RCM versus punch biopsy for diagnosing and subtyping clinically suspected primary BCC. Read More

    ΔNp63α promotes adhesion of metastatic prostate cancer cells to the bone through regulation of CD82.
    Oncogene 2017 Apr 3. Epub 2017 Apr 3.
    Gene Regulation, Stem Cells and Cancer Program, Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain.
    ΔNp63α is a critical mediator of epithelial development and stem cell function in a variety of tissues including the skin and breast, while overexpression of ΔNp63α acts as an oncogene to drive tumor formation and cancer stem cell properties in squamous cell carcinoma. However, with regards to the prostate, while ΔNp63α is expressed in the basal stem cells of the mature gland, during adenocarcinoma development, its expression is lost and its absence is used to clinically diagnose the malignant state. Surprisingly, here we identify a sub-population of bone metastatic prostate cancer cells in the PC3 cell line that express ΔNp63α. Read More

    Comparative study of the calculated risk of radiation-induced cancer after photon- and proton-beam based radiosurgery of liver metastases.
    Phys Med 2017 Mar 30. Epub 2017 Mar 30.
    Department of Physics - Medical Radiation Physics, Stockholm University, Stockholm, Sweden.
    Introduction: The potential of proton therapy to improve the sparing of the healthy tissue has been demonstrated in several studies. However, even small doses delivered to the organs at risk (OAR) may induce long-term detriments after radiotherapy. In this study, we investigated the possibility to reduce the risk of radiation-induced secondary cancers with intensity modulated proton therapy (IMPT), when used for radiosurgery of liver metastases. Read More

    Atypical breast adenosquamous carcinoma following acute myeloid leukemia in a middle-aged woman: A case report.
    Mol Clin Oncol 2017 Feb 3;6(2):271-275. Epub 2017 Jan 3.
    Division of Hematology and Medical Oncology, Department of Medicine, School of Medicine, Mashhad University of Medical Science, Mashhad, Iran.
    Adenosquamous carcinoma of the breast is a rare cancer that develops as glands and tubules admixed with solid nests of squamous cells in a spindle cell background. Furthermore, its occurrence following AML is also rare. To the best of our knowledge, based on a review of the relevant literature, thus far there have not been any welldocumented cases. Read More

    Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma.
    Future Oncol 2017 Mar 28. Epub 2017 Mar 28.
    Translational Skin Cancer Research, German Cancer Consortium (DKTK), Partner site Essen Düsseldorf, University Hospital Essen, Essen, Germany.
    Aim: Merkel cell carcinoma (MCC) is a rare neuroendocrine, cutaneous malignancy with poor prognosis once metastasized. The aim of this study was to conduct a systematic literature review to assess clinical outcomes associated with chemotherapy regimens in metastatic MCC.

    Materials & Methods: Embase(®), MEDLINE(®), MEDLINE(®)-In-Process and CENTRAL were searched for studies published in January 2016. Read More

    Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
    Lancet Diabetes Endocrinol 2017 May 23;5(5):355-366. Epub 2017 Mar 23.
    Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands. Electronic address:
    Background: Several pharmacological treatment options are available for type 2 diabetes; however, many patients do not achieve optimum glycaemic control and therefore new therapies are necessary. We assessed the efficacy and safety of semaglutide, a glucagon-like peptide-1 (GLP-1) analogue in clinical development, compared with insulin glargine in patients with type 2 diabetes who were inadequately controlled with metformin (with or without sulfonylureas).

    Methods: We did a randomised, open-label, non-inferiority, parallel-group, multicentre, multinational, phase 3a trial (SUSTAIN 4) at 196 sites in 14 countries. Read More

    Metastatic neuroendocrine carcinoma in the skin.
    Dermatol Online J 2017 Jan 15;23(1). Epub 2017 Jan 15.
    Department of Dermatology, University of Texas McGovern Medical School at Houston.
    Cutaneous metastases secondary to neuroendocrinetumors are rare. Herein we report a case of a 75-yearoldwoman who presented with a rare cutaneousmetastatic disease. She was previously diagnosed withmetastatic neuroendocrine carcinoma of unknownprimary, with metastases to liver, lung, and bone. Read More

    Signet-ring Cells in the Skin: A Case of Late-onset Cutaneous Metastasis of Gastric Carcinoma and a Brief Review of Histological Approach.
    Dermatol Reports 2016 Jun 4;8(1):6819. Epub 2017 Jan 4.
    Department of Dermatology and Venerology, Kirikkale University , Turkey.
    Up to 10% of patients with visceral malignancies develop skin metastases during their clinical course and these metastases constitute about 2% of all skin cancers. Skin metastasis may be the first sign of a clinically silent visceral cancer or represent recurrence of an internal malignancy. In both situations, they are associated with poor prognosis, which can partly be attributed to underdiagnosis. Read More

    GATA3 and MYB Expression in Cutaneous Adnexal Neoplasms.
    Am J Dermatopathol 2017 Apr;39(4):279-286
    *Departments of Pathology, Porto Medical School and Sao Joao Hospital, Porto, Portugal; †Departments of Pathology, William Beaumont School of Medicine, Royal Oak, MI; ‡Departments of Pathology, Duke University Medical Center, Durham, NC; and §Departments of Pathology, Harvard Medical School and Massachusetts General Hospital, Boston, MA.
    Knowledge of staining pattern of certain immunostains might be useful in the classification of cutaneous adnexal tumors that can have clinical importance. We studied GATA3 and MYB expression in archival materials of 220 adnexal tumors comprised of sebaceous carcinomas, follicular tumors, apocrine carcinoma, predominantly apocrine tumors, predominantly eccrine tumors, and others including adenoid cystic carcinomas. Nuclear GATA3 expression was seen in 70% (153/220) of cases, including sebaceous carcinoma (93%), apocrine carcinoma (93%), follicular neoplasms (100%), and predominantly apocrine neoplasms (69%), yet only 38% of predominantly eccrine neoplasms. Read More

    Complement Component C3 and Complement Factor B Promote Growth of Cutaneous Squamous Cell Carcinoma.
    Am J Pathol 2017 May 17;187(5):1186-1197. Epub 2017 Mar 17.
    Department of Dermatology, University of Turku and Turku University Hospital, Turku, Finland; MediCity Research Laboratory, University of Turku, Turku, Finland. Electronic address:
    Cutaneous squamous cell carcinoma (cSCC) is one of the most common metastatic skin cancers with increasing incidence. We examined the roles of complement component C3 and complement factor B (CFB) in the growth of cSCC. Analysis of cSCC cell lines (n = 8) and normal human epidermal keratinocytes (n = 11) with real-time quantitative PCR and Western blotting revealed up-regulation of C3 and CFB expression in cSCC cells. Read More

    Fine-needle aspiration of metastatic melanoma presenting as bilateral breast cysts.
    Diagn Cytopathol 2017 May 20;45(5):446-451. Epub 2017 Mar 20.
    Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland.
    Melanoma is the second most common non-hematopoietic malignancy after carcinomas to metastasize to the breast and often appears as a well-circumscribed, dense nodule on imaging. Although metastatic lesions presenting as bilateral cysts have been reported, this presentation is not common and may mimic benign breast cysts. We present a challenging case of metastatic melanoma presenting as bilateral breast cysts with spindled cytomorphology in a patient with a history of mammary carcinoma. Read More

    Ovarian carcinoma presenting as cutaneous nasal metastasis.
    An Bras Dermatol 2016 Sep-Oct;91(5 suppl 1):101-104
    Hospital Garcia de Orta - Almada, Portugal.
    Metastatic ovarian cancer uncommonly presents with skin metastasis. When present, skin metastases of ovarian cancer are usually localized in the vicinity of the primary tumor. We report a case of a 58-year-old woman with a rapid growing erythematous, well-defined nodule localized on the left nasal ala. Read More

    Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers.
    Clin Genet 2017 Mar 16. Epub 2017 Mar 16.
    Département de Médecine Oncologique, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
    We addressed uncertainties regarding hereditary leiomyomatosis and renal cell carcinoma (HLRCC) by exploring all French cases, representing the largest series to date. Fumarate hydratase (FH) germline testing was performed with Sanger sequencing and qPCR/MLPA. Enzyme activity was measured when necessary. Read More

    Simultaneous vascularized bony reconstruction of the maxilla and mandible using a single fibula: A case report.
    Microsurgery 2017 Mar 13;37(3):243-247. Epub 2017 Mar 13.
    Department of Plastic Surgery, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
    Simultaneous maxillary and mandibular reconstruction is exceedingly rare. These are complicated cases, requiring consideration of multiple variables: defect components, donor site morbidity, recipient vessels, and so forth. We describe a unique case of secondary maxillary/mandibular reconstruction in a 59-year-old male. Read More

    Bilateral Lymphatic Spread of Metastatic Basal Cell Carcinoma.
    Plast Reconstr Surg Glob Open 2016 Dec 23;4(12):e1182. Epub 2016 Dec 23.
    Department of Surgery, Division of Surgical Oncology, 987400 Nebraska Medical Center, University of Nebraska Medical Center, Omaha, Neb.
    Herein, we report a case of a patient with an abnormal skin lesion that remained unchecked by medical professionals for approximately 20 years. Upon physical examination in the emergency department for a fractured hip, an infiltrative mass was incidentally discovered. The neoplasm was noted to have progressed from an eraser-sized mass to a 3. Read More

    mFOLFOX6 Plus Panitumumab Versus 5-FU/LV Plus Panitumumab After Six Cycles of Frontline mFOLFOX6 Plus Panitumumab: A Randomized Phase II Study of Patients With Unresectable or Advanced/Recurrent, RAS Wild-type Colorectal Carcinoma (SAPPHIRE)-Study Design and Rationale.
    Clin Colorectal Cancer 2017 Mar 1. Epub 2017 Mar 1.
    Tokai Central Hospital, Kakamigahara, Japan.
    Background: In Japan, oxaliplatin (OXA)/5-fluorouracil (5-FU)/leucovorin (LV)-the mFOLFOX6 regimen-is the most frequently used first-line chemotherapy backbone for metastatic colorectal cancer. However, peripheral nerve disorders caused by OXA during mFOLFOX6 therapy can decrease patients' quality of life. OXA can be safely discontinued from a FOLFOX regimen after 6 cycles during first-line therapy. Read More

    Planning study for Merkel cell carcinoma based on the relapse pattern.
    Radiother Oncol 2017 Apr 8;123(1):154-157. Epub 2017 Mar 8.
    Radiation Oncology, Charité University Medicine Berlin, Germany.
    Purpose: To develop a technique for radiation (RT) of in-transit path ways (IT) in Merkel cell carcinoma.

    Method: In the planning study, IT were ink-marked on the skin during sentinel lymphscintigraphy and wire-marked in planning-CT. Pre- and post-operative planning-CTs were acquired. Read More

    New developments in the biology and the treatment of metastatic Merkel cell carcinoma.
    Curr Opin Oncol 2017 Mar 9. Epub 2017 Mar 9.
    aDepartment of Dermatology, University of Lübeck, Lübeck bTranslational Skin Cancer Research, German Cancer Consortium (DKTK), Department of Dermatology and the West German Cancer Center, Essen University Hospital, Essen, Germany.
    Purpose Of Review: Patients with stage IIIB und IV metastatic Merkel cell carcinoma (mMCC), who are not suitable candidates for surgery or radiotherapy, are unlikely to achieve lasting remission or tumor control by chemo or targeted therapy. In the majority of cases, the tumor arises from viral carcinogenesis associated with the Merkel cell polyomavirus (MCPyV). In MCPyV-negative tumors with a presumable ultraviolet carcinogenesis, a high mutational burden resulting in neoantigens was discovered. Read More

    Reduced H3K27me3 expression in Merkel cell polyoma virus-positive tumors.
    Mod Pathol 2017 Mar 10. Epub 2017 Mar 10.
    Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
    Merkel cell carcinoma is a primary cutaneous neuroendocrine carcinoma, which once metastatic is difficult to treat. Recent mutation analyses of Merkel cell carcinoma revealed a low number of mutations in Merkel cell polyomavirus-associated tumors, and a high number of mutations in virus-negative combined squamous cell and neuroendocrine carcinomas of chronically sun-damaged skin. We speculated that the paucity of mutations in virus-positive Merkel cell carcinoma may reflect a pathomechanism that depends on derangements of chromatin without alterations in the DNA sequence (epigenetic dysregulation). Read More

    Avoiding Facial Incisions with Midface Free Tissue Transfer.
    Plast Reconstr Surg Glob Open 2017 Feb 22;5(2):e1218. Epub 2017 Feb 22.
    Division of Plastic and Reconstructive Surgery, Louisiana State University Health Sciences Center School of Medicine, New Orleans, La.; Department of Plastic and Reconstructive Surgery, Johns Hopkins Medical Institute, Baltimore, Md.; Hansjörg Wyss Department of Plastic Surgery, New York University Langone Medical Center, New York, N.Y.; and Division of Plastic Surgery, University of Montreal, Montreal, QC.
    Background: We have adopted an intraoral microsurgical anastomosis to the facial vessels to eliminate the need for any visible facial incisions.

    Methods: Cadaveric dissection was used to demonstrate accessibility of the facial artery and vein through an intraoral approach. Additionally, 5 patients underwent free tissue transfer for reconstruction of major defects of the midface through an intraoral, transmucosal approach, obviating the need for visible skin incisions. Read More

    [Malignant transformation of an eccrine spiradenoma].
    Ann Dermatol Venereol 2017 Mar 27;144(3):203-207. Epub 2016 Oct 27.
    Service de pathologie, centre hospitalier Lyon sud, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite, France.
    Introduction: Malignant eccrine spiradenoma is a rare and aggressive tumor, developed on the epithelium of eccrine sweat glands. Typically, it occurs after malignant transformation of benign eccrine spiradenoma, but sometimes it happens de novo.

    Observation: We report a case of malignant eccrine spiradenoma in a 62-year-old woman. Read More

    Postoperative Radiotherapy in Salivary Gland Carcinoma: A Single Institution Experience.
    Gulf J Oncolog 2017 Jan;1(23):26-32
    Department of Otolaryngology, School of Medicine, Inonu University, Malatya, Turkey.
    Background: Salivary gland carcinoma are rare tumors and the main treatment is surgical. The addition of radiotherapy to surgery decreases locoregional relapses in high risk patients. Aim of our study is to retrospectively evaluate local control and survival and the factors affecting them in patients who received postoperative radiotherapy. Read More

    Medial canthal defects following tumour excision: To reconstruct or not to reconstruct?
    Orbit 2017 Apr 7;36(2):64-68. Epub 2017 Mar 7.
    a University Hospital of Coventry & Warwickshire , Coventry , West Midlands , United Kingdom.
    Laissez-faire following excision of peri-ocular tumours has been described, but is not universally well established. We describe our experience with laissez-faire for managing medial canthal defects following tumour excision and compare our outcomes with full thickness skin grafts. Retrospective comparative case series of 68 patients who underwent reconstruction of a medial canthal defect using laissez-faire with sutured Sorbsan (LFS) (n = 36) or a full thickness skin graft (FTSG) (n = 32) at the same centre. Read More

    Association of Oncogenic Mutations in Patients With Advanced Cutaneous Squamous Cell Carcinomas Treated With Cetuximab.
    JAMA Dermatol 2017 Apr;153(4):291-298
    Department of Dermatology, University Hospital of Nice, France.
    Importance: Cetuximab was recently proposed for advanced cutaneous squamous cell carcinomas (cSCC); however, its efficacy is inconsistent and identification of predictive biomarkers for response is necessary.

    Objective: To search for somatic mutations of the HRAS, KRAS, NRAS, BRAF, and EGFR genes in patients with advanced cSCC treated with cetuximab; and to investigate the efficacy and tolerance of cetuximab according to these mutations.

    Design, Setting, And Participants: A multicentric and retrospective study of 31 patients (22 men, 9 women) with histologically confirmed advanced cSCC carried out in 1 department of dermatology and 2 departments of medical oncology in France between January 2008 and December 2014. Read More

    1 OF 163